Business
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
ALAMEDA, Calif.--(BUSINESS WIRE)-- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing
About this update from Vivani Medical, Inc.
[{"type":"text","content":" ALAMEDA, Calif.--(BUSINESS WIRE)--\nVivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024.\n\nVivani invites individual and institutional investors as well as advisors and analysts to attend its interactive presentation at the Emerging Growth Conference. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s President and CEO, Adam Mendelsohn, Ph.D. in real time. Dr. Mendelsohn will deliver a company overview and may subsequently open the floor to questions. Please submit questions in advance to [email protected].\n\nVivani will be presenting at 1:10 p.m. Eastern Time for 30 minutes.\n\nPlease register at the following link to attend the conference and receive any updates released in follow up to the Vivani presentation: https://goto.webcasts.com/starthere.jsp?ei=1677125&tp_key=64e020ccee&sti=vani\n\nAn archived webcast will be made available after the conference on EmergingGrowth.com and on the Emerging Growth YouTube channel, http://www.YouTube.com/EmergingGrowthConference.\n\nAbout Vivani Medical, Inc.\n\nLeveraging its proprietary NanoPortalTM platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Vivani’s emerging pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. The semaglutide implant has the added potential benefit of once-yearly administration. NPM-119 refers to the Company’s Type 2 Diabetes development program utilizing a six-month, subdermal exenatide implant. Both the NPM-115 and NPM-119 programs utilize exenatide based products with a higher-dose associated with the NPM-115 program for chronic weight management in obese or overweight patien...